This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of +9.30% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in InMode Stock?
by Zacks Equity Research
Investors need to pay close attention to InMode stock based on the movements in the options market lately.
Envista (NVST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About InMode Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to InMode stock based on the movements in the options market lately.
Company News for Apr 29, 2025
by Zacks Equity Research
Companies In The News Are: DPZ, RVTY, OPRA, INMD.
InMode (INMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of -6.06% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Envista (NVST) Q1 Earnings Expected to Decline
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day.
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
by Urmimala Biswas
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.
Is InMode (INMD) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Do Options Traders Know Something About InMode (INMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to InMode (INMD) stock based on the movements in the options market lately.
InMode (INMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 22.81% and 0.18%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: InMode (INMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is InMode (INMD) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy InMode (INMD) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing InMode (INMD) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InMode (INMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 13.33% and 0.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Zynex (ZYXI) delivered earnings and revenue surprises of -50% and 3.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 12.50% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?